Adc Therapeutics SA(ADCT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 6:54 PM ET (Korea 10/28 07:54)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.66 | Insider Own | 22.42% | Shs Outstand | 127.4M | Perf Week | 4.61% |
| Market Cap | 0.20B | Forward P/E | - | EPS next Y | 10.3% | Insider Trans | - | Shs Float | 99.0M | Perf Month | 26.19% |
| Enterprise Value | 0.10B | PEG | - | EPS next Q | -0.21 | Inst Own | 57.98% | Short Float | 6.4% | Perf Quarter | 44.55% |
| Income | -0.10B | P/S | 2.55 | EPS this Y | 32.81% | Inst Trans | -4.06% | Short Ratio | 4.12 | Perf Half Y | -57.82% |
| Sales | 0.08B | P/B | - | EPS next 5Y | 32.85% | ROA | -32.25% | Short Interest | 6.34M | Perf YTD | -54.96% |
| Book/sh | -1.79 | P/C | 0.93 | EPS past 3/5Y | 17.66% 21.5% | ROE | - | 52W High | -68.07% ($4.98) | Perf Year | -62.94% |
| Cash/sh | 1.72 | P/FCF | - | Sales past 3/5Y | -27.09% - | ROIC | - | 52W Low | 103.95% ($0.78) | Perf 3Y | 127.14% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 57.71% | Gross Margin | 88.42% | Volatility(W/M) | 8.89% 11.21% | Perf 5Y | -94.32% |
| Dividend TTM | - | EV/Sales | 1.27 | Sales Y/Y TTM | 3.03% | Oper. Margin | -121.82% | ATR (14) | 0.14 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.97 | EPS Q/Q | 78.53% | Profit Margin | -121.77% | RSI (14) | 57.45 | Recom | 2.2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.03 | Sales Q/Q | 2.17% | SMA20 | 9.02% ($1.46) | Beta | 1.86 | Target Price | $2.62 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | 24.82% ($1.27) | Rel Volume | 0.81 | Prev Close | $1.51 |
| Employees | 193 | LT Debt/Eq | - | EPS/Sales Surpr. | 49.07% 1.91% | SMA200 | -36.73% ($2.51) | Avg Volume(3M) | 1.54M | Price | $1.59 |
| IPO | 2020/5/15 | Option/Short | Yes/Yes | Trades | 2080 | Volume | 1,250,201 | Change | 5.3% |
🧬 ADCT Therapeutics is a commercial-stage oncology-focused biotech developing treatments for hematologic cancers and solid tumors based on antibody-drug conjugate (ADC) technology. Its lead product is an FDA-approved CD19-targeted antibody-drug conjugate therapy, marketed for patients with relapsed or refractory diffuse large B-cell lymphoma.
Over the past 1 year, on the lower side
68% below its 1-year high.
Traded about as much as usual. That is 81% of its average volume.
ADCT has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +32.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $255. Peers typically go for $197.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -94.3%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 58.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #50 of 83 in the industry
Based on market cap of $203M.
LFCR#48 Lifecore Biomedical Inc $244M PER - 
SIGA#49 SIGA Technologies Inc $230M PER - ADCT#50 Adc Therapeutics SA $203M PER - 
AKBA#51 Akebia Therapeutics Inc $184M PER - 
GLAS#52 Glass House Brands Inc $181M PER - 
FAQ
What kind of company is ADCT?
ADCT belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ADCT?
The market cap of ADCT is approximately $203M, ranking 4,002 within its sector.
What is the 52-week high and low for ADCT?
ADCT has recorded a 52-week high of $4.98 and a low of $0.78.
